- R&D Pipeline
- Season 2 (2021-2030)
| Modality | Indication | Targets | Stage | Company | Project No. | Detail | |
|---|---|---|---|---|---|---|---|
| 1 | Candidate optimization of ARBM-101 as an innovative Wilson's disease drug | ||||||
| Peptide | Wilson disease | Cu2+ | Candidate | ARBORMED | RS-2023-00218925 | ||
| 2 | Multi-modal cell-penetrating peptide for diabetic foot ulcer | ||||||
| Peptide | Diabetic foot ulcer | pre-let7 miRNA | Preclinical | StemMeditech Inc. | RS-2022-00165887 | ||
| 3 | Nonclinical Drug Development of anti-achondroplasia therapy for activated FGFR3 inhibition with NPR-B-Targeting Peptide | ||||||
| Peptide | Achondroplasia | NPR-B | Preclinical | Peptron, Inc | HN21C1247 | ||